abbvie stock forecast 2030

ABBV-916 is targeting Alzheimer's and it is an anti-amyloid antibody, with a similar mechanism of action ("MoA") to recently approved Leqembi, developed by Biogen (BIIB) / Eisai, and likely soon-to-be approved Donanemab, developed by Eli Lilly. Should I buy or sell AbbVie stock right now? I have speculatively assigned peak sales of $2bn, although it should be noted that success here is far from guaranteed, although if AbbVie did succeed with ABBV916 sales could be 2 or 3x higher than my forecast. Nineteen analysts predict that AbbVie's share price will increase in the coming year, reaching $165.00. It revealed that patients with moderate to severe Crohns disease receiving Abbvies Rinvoq achieved steroid-free clinical remission in significantly higher numbers than patients receiving a placebo. As we can see, as per management's guidance revenues fall between 2022 and 2023, before recovering and growing in each year after. However, there are some general principles that can be followed in order to improve the accuracy of stock price predictions. The division delivered >$1.65bn in sales in Q2'22, up >15% year-on-year, and with Vraylar, Ubrelvy and possibly Qulipta all earmarked for blockbuster sales - $4bn in the case of Vraylar - my forecasting suggests this division could double in size by 2030, from ~$6.6bn revenues generated in FY22, to >$13.5bn by 2030. The company may not generate as much excitement as some of the other members of the "Big 8" - most notably Eli Lilly and its weight loss franchise, but the path to revenue growth, expanding margins and a growing share price is clear. In-depth profiles and analysis for 20,000 public companies. Refer to our. PEG Ratios above 1 indicate that a company could be overvalued. The company is a member of the Fortune 100 and one of the Fortune 100s Best Companies To Work For. AbbVie stock forecast 2022 - 2025 - 2030 with analysis AbbVie stock stood at $162.110000610352 on 2022-03-31. forecast for 2023 is $159.42, forecast for 2024 is $156.65, forecast for 2025 is $139.68, forecast for 2026 is $124.48, Payout ratios above 75% are not desirable because they may not be sustainable. AbbVie's success - as its shareholders will doubtless be aware - stems from the runaway success of its immunology drug Humira, which is indicated for a range of autoimmune conditions, including Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, Hidradenitis Suppurativa and Ankylosing spondylitis. Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year., ABBV has done very well to add to its impressive gains from the past couple of years. According to analysts' consensus price target of $161.12, AbbVie has a forecasted upside of 3.2% from its current price of $156.06. For full year 2022, Abbvie predicted the adjusted diluted EPS guidance range at $14.00 to $14.20 and $13.92 to $14.12. Their ABBV share price forecasts range from $140.00 to $200.00. My No. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Skyrizi has also been approved to treat Crohn's Disease, an added bonus and another multi-billion dollar market. Forecast target price for 03-06-2023: $ 152.58. All content of the Dow Jones branded indices S&P Dow Jones Indices LLC 2019 and/or its affiliates. Is this happening to you frequently? Retail sales were up but so was inflation which meant more volatility for stocks. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.12. Neuroscience looks highly promising too, and aesthetics capable of driving some respectable growth driven by old stager Botox. The AbbVie of today has 5 thriving divisions - Immunology, Oncology, Neuroscience, Aesthetics, and Eye Care - with the latter 3 divisions acquired from Allergan as part of AbbVie's $63bn takeover of that company. AbbVie probably does not want to be recognized as simply an immunology giant however, it wants to be substantially more diversified and like all major Pharma's it has a strong long-term focus on oncology. ABBV Stock 12 Months Forecast. The analysts 12-month consensus ABBV stock price target was $159.75. With Skyrizi and Rinviq - two assets developed in-house - performing so well, however, perhaps we should give management the benefit of the doubt. The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. AbbVie Stock: ABBV Overview and Dividend Potential, Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor (ABBV), Analyst Confidence in Eli Lilly Boosted by Product Pipeline (ABBV), Johnson & Johnson: Taking The Bull By The Horns? Ltd., AbbVie Overseas S. r.l., AbbVie Oy, AbbVie Participaes Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. At their peak, according to a slide from AbbVie's presentation at the JPMorgan (JPM), these 2 drugs are expected to generate more revenues than Humira at its peak. In the next year, analysts predict that Revenue will reach C$253.83M - an increase of 3.50%. (my table and forecasts). How do I arrive at my share price target? All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn. Different trading strategies will suit different investment goals with short or long-term focus. The above table shows quarterly and annual product revenues going back to FY20, whilst the last 4 columns show revenue growth percentage between FY20 and FY21, then revenue growth between Q2'21 and Q2'22, the sequential (quarter on quarter) growth, followed by product sales as a percentage of revenues. If you have an ad-blocker enabled you may be blocked from proceeding. According to the Abbvie stock technical analysis, as of 30 June, the Relative Strength Index (RSI) was pointing to neutral at 62.18. Earnings for AbbVie are expected to decrease by -0.55% in the coming year, from $11.00 to $10.94 per share. 16 analysts have issued 12-month price targets for AbbVie's shares. View the best growth stocks for 2023 here. Neurology also looks strong although aesthetics, eye care and oncology have something to prove. I write about Biotech, Pharma and Healthcare stocks and share investment tips. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. Please disable your ad-blocker and refresh. . The consensus rating was moderate buy based on 16 analysts ratings, with 10 recommending buy, five hold and sell. In February, a Phase 3 induction study saw positive top-line results. Both of these assets appear to be doing the job they were intended for - protecting AbbVie's dominance in various auto-immune markets - and now represent ~13% of AbbVie's total revenue generation. We now expect global sales for Skyrizi to reach more than $10 billion in 2025, an increase of $2.5 billion versus our previous guidance, reflecting higher performance across basically all of the indications. And we remain confident in our ability to achieve total sales of more than $9 billion by 2029. AbbVie Fair Value Forecast for 2023 - 2025 - 2030 In the last two years, AbbVie's Price has grown, increasing from $91.55 to $130.05 - an increase of 42.06%. According to 23 major analysts, AbbVie's Fair Value will fall by 5.43% in the next year, reaching $122.98. The average Abbvie stock price prediction forecasts a potential upside of 7.07% from the current ABBV share price of $155.27. AbbVie will have to drop its price point to compete with the generics however, plus there is the 10% of the market it is not covered for, so an overall 20% decline in revenues in 2023 seems accurate. That certainly won't derail the oncology division however. That was below AbbVie stock analysts' view for $14.16. According to CEO Gonzalez: Over the long-term, aesthetics continues to be an extremely attractive underpenetrated market with significant growth potential. CFDs are complex leveraged instruments and come with a high risk of losing money. The average ABBVIE INC stock forecast 2023 represents a 1.86% increase from the last price of $153.729995727539. Skyrizi - which inhibits the activities of IL-23 - a naturally occurring cytokine that is involved in inflammatory and immune responses - and Rinvoq - a member of the janus kinase inhibitor drug class - fit this profile. The "King Of Quants" sees 10X potential Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. In the last four years, Johnson & Johnson's Free Cash Flow has fallen from $18.53B to $17.00B - a 8.28% decrease. Factset: FactSet Research Systems Inc.2019. AbbVie had a net margin of 20.39% and a trailing twelve-month return on equity of 154.52%. I have no business relationship with any company whose stock is mentioned in this article. To date, the company had invested more than $50 billion into research through more than 250 partnerships. The company earns $11.84 billion in net income (profit) each year or $6.61 on an earnings per share basis. I'm on twitter @edmundingham. Other products such as Mavyret and Creon appear to have many more years of blockbuster sales ahead of them, although it is interesting to note that AbbVie no longer reports revenues from its Women's Health division, and scarcely mentions it. Currently, the company has a "stable" rating, but that must be maintained or investors will perceive the company as unsafe to invest in and that will drag the share price down rapidly. That same month, the FDA extended the review period for Skyrizi (risankizumab), a treatment drug for moderate to severe Crohns disease in patients aged 16 and older. In this article we take a closer look at the Abbvie stock forecast, after analysing the firms latest earnings, price moving news and analyst comments. Management believes these 2 drugs could one day generate $15bn in peak sales, going a long way to solving the Humira loss of exclusivity ("LOE") problem. In other words, management believes the LOE of Humira - despite it being the world's best-selling drug - will not hinder growth at the company. Any company is likely to struggle if sales of its best-selling asset begin to decline by ~20% per annum, which is traditionally the rate at which patent expired drugs' sales slip, but when the drug in question accounts for >35% of a company's sales, as Humira does, the situation becomes even more serious. on the strength of its future rather than present portfolio. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. The obvious advantages of a "one and done" permanent cure make them potentially very lucrative therapies. In my model I have then reduced revenues by 20% between 2024 - 2026, and then by 10% per annum between 2027 - 2030. Our daily ratings and market update email newsletter. This figure could eventually end up substantially larger - according to Gonzalez: We've begun to see some very exciting data from several solid tumor programs, including our anti-GARP antibody ABBV-151, and our PTK7 ADC, ABBV-647. See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. Abbvie Inc quote is equal to 152.710 USD at 2023-02-27. (844) 978-6257. Neuroscience is one of AbbVie's most intriguing divisions and perhaps the hardest to model. Pessimistic target level: 151.42 Optimistic target level: 154.48 ABBV (ABBV) Monthly Stock Prediction for 2023 Full forecast for 2023 AbbVie forecast for this year (6.33% Upside) Based on 15 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. Abbvies haematologic oncology portfolio, neuroscience portfolio and aesthetics portfolio reported net revenues of $1.65bn, $1.49bn and $1.37bn, respectively. When I began this post it was in my mind to give AbbVie stock a "Hold" rating owing to an underwhelming - on some levels - set of Q2'22 earnings, some concerns around high revenue generating products such as Imbruvica, Juvederm, and Restasis, the disappearance of the Women's Health division, the imminent LOE for Humira and the high levels of debt. What is the dividend yield for AbbVie? In this post, I will discuss Q2'22 results, as well as the long-term outlook for AbbVie based on the latest information, goals, risks, and financial modeling analysis, to try to establish a target price for AbbVie stock. (JPM Healthcare conference presentation), Skyrizi's performance has been particularly eye-catching. As per management's guidance, I am modelling for $5.7bn of revenues in 2023, with growth beginning to accelerate substantially from 2025 / 26 onwards. The company didn't offer a . The 21 analysts offering 1 year price forecasts for ABBV have a max estimate of and a min estimate of . Drug development has not traditionally been one of AbbVie's strengths - it has not had to be - but we ought to see the positive results of heavy investment into the oncology pipeline over the next 5-7 years, and by 2030, I believe this division could account for >17% of AbbVie's total revenues. The company also successfully completed the acquisition of Syndesi Therapeutics SA in March. There has been a raft of price-moving news for Abbvie, which may positively affect the stock price. Richard A. Gonzalez has an approval rating of 88% among the company's employees. That led to an overall 6% year-on-year gain of 6%, and a 13% sequential gain. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Forecasts shouldnt be used as a substitute for your own research. ABBV closed at $152.49 on 29 June, which was above its 200-day moving average (MA) of 136.42, indicating a bullish signal for the stocks price movement ahead, according to data from TradingView. 164.71 0.00 0.00%. Only you can design whether Abbvie stock is the right investment for you. If signs point to that happening I will likely be revising my target price upwards again, but I am playing it more conservative as nobody truly knows the scale of losses after the Humira LOE. Specifically, they have bought $0.00 in company stock and sold $23,102,528.00 in company stock. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Snowflake Reports Weak Guidance: Is the Growth Snowflake Melting? The median estimate represents a +5.72% increase from the last price of 156.07. Bhd., AbbVie Sp. The company issued revenue guidance of -. 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. The average price target represents a 6.33% change from the last price of $153.90. I wrote this article myself, and it expresses my own opinions. My calculation is that Humira revenues in 2023 will be 80% of the 2022 figure, or $16.7bn. Finally, eye-care - another division inherited from Allergan - has been performing well for AbbVie although I am not expecting particularly strong growth from the current product portfolio. As such, I have decreased my own expectations for 2022 based on simply doubling H1'22 revenues to get a FY22 figure, and downgrading growth expectations to 3% per annum until 2026. If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth. AbbVie income statement forecast (My table and assumptions). As of 30 June, analysts price predictions compiled by MarketBeats and long-term forecasts by Wallet Investor projected that the ABBV stock price could rise. Management initially blamed slow take-up post pandemic for the drug's declining sales, but Gonzalez also told JPM Conference attendees that "new competitive entrants has significantly lowered our sales expectations for Imbruvica". AbbVie is led by CEO and Chairman Rick Gonzalez - likely the only Pharma CEO who lacks a college degree - who has successfully defended Humira from generic drug competition by adopting a controversial strategy of continually applying for new patents related to minor changes in manufacturing methods or administration, often referred to as a "patent thicket". AbbVie has fought off patent challenges against Humira for years longer than expected, and despite losing exclusivity in Europe in 2020, a series of price hikes and market dominance in the US in indications such as Rheumatoid Arthritis ("RA"), Psoriatic Arthritis ("PsA"), Crohn's Disease ("CD"), and Ulcerative Colitis ("UC") - have enabled the drug's sales revenues to keep growing. (NYSE: ABBV) Abbvie's current Earnings Per Share (EPS) is $6.65. There are still very few approved therapies, although that could change with Crispr Therapeutics (CRSP) / Vertex (VRTX) Sickle Cell Disease therapy leading the charge in 2023. What guidance has AbbVie issued on next quarter's earnings? Since then, ABBV stock has decreased by 3.4% and is now trading at $156.06. It is important to do your own research, and remember that your decision to trade depends on your attitude to risk, your expertise in the market, the spread of your investment portfolio and how comfortable you feel about losing money. 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. AbbVie is a leader in ESG and sustainability. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth New research suggests Depakote ingredient could have a new clinical function. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. That is interesting to me as I think it suggests management will need to commercialize more assets if it wants to hit that target. View our ABBV earnings forecast. In my modeling table above, I estimate Humira sales will decline by 25% between 2022 and 2023, to ~$16bn, although some of that lost revenue will be gobbled up by Skyrizi/Rinvoq. After creating the income statement I prepare the discounted cash flow/EBITDA multiple analysis. Below, I will outline how I see AbbVie putting the Humira LOE firmly behind it, and driving the high single digit percentage annual growth management has promised. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. approvals of Humira, Skyrizi, Rinvoq (AbbVie JPM Healthcare conference presentation). The weighted average cost of capital I estimate to be 9.6% - I tend to use a WACC of 10% for most Big Pharma analysis. Ever since its split from Abbott Laboratories (ABT) in 2012 AbbVie (NYSE:ABBV) has delivered strong returns for investors - its stock price having risen overall from $30, to $149 per share at the time of writing - trading down slightly from its all-time high of >$160 achieved in early December last year. target price for AbbVie stock based on DCF / EBITDA multiple analysis (my table and assumptions). First of all, as shown in the table above I forecast product sales out to 2030. What that means is, essentially it will be on formulary with biosimilars, but there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. When looking for ABBV stock forecasts, its important to bear in mind that analysts forecasts can be wrong. The development of these 2 drugs has been very quick by drug development standards, and to date both have performed exceptionally well. According to the algorithm-based forecaster Wallet Investor in its Abbvie stock forecast for 2022, the price could reach $169.852 by the end of December, $199.491 by 2023 and $229.304 by 2024. You should do your own research and never invest money you cannot afford to lose. Let's begin our analysis with the immunology division. Perhaps this is an example of how ruthless management can be when encountering falling sales, and a warning that not all company divisions are guaranteed to thrive. AbbVie's stock was trading at $161.61 on January 1st, 2023. The median. To be sure, AbbVie is modeling for a tough year in 2023 for the aesthetics market. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Shares are consolidating with a buy. I have no business relationship with any company whose stock is mentioned in this article. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. The company has a robust pipeline of new products that are in some stage of clinical trials. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Not only do these companies pay handsome dividends, they typically grow revenues every year and generate wide profit margins which leads to share price upside. call (03) 8658 0539 support.au@capital.com. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. Naturally, if there is a more effective and safe drug than Humira available for the same indication, then physicians are likely to prescribe it over Humira, or a Humira biosimilar. AbbVie's Q2'22 earnings threw up some positives and negatives for investors to contemplate. The majority of the biosimilar (more sophisticated versions of generic drugs) imitations of Humira that will contest for market share with the original will launch around the middle of 2023, including versions developed by Pfizer (PFE), Boehringer Ingelheim, Organon (OGN), Biocon, Coherus Biosciences (CHRS) and Sandoz, whilst Amgen's (AMGN) Amjevita is permitted to launch in January. Although investing in AbbVie isn't riskless, it is advisable based on what we know about the company. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. AbbVie Aesthetics / Neurology revenues forecasts to 2030 (my table and assumptions) . It's hard to argue against Skyrizi and Rinvoq's performance to date, however, and with the total addressable market across all immunology indications likely well in excess of $100bn, I feel fairly comfortable that AbbVie can grow this division's revenues even as the world's biggest ever selling drug exits stage left. Export data to Excel for your own analysis. Data from two Phase 3 induction studies and one maintenance study supported the approval. There is an element of risk to that as clinical trial failures are common, even for a giant like AbbVie, and even CEO Gonzalez may be forced to backtrack on some of his blockbuster sales projections. This has been in spite of a string of macroeconomic headwinds such as the ongoing Russia-Ukraine war that has contributed to record high inflation in the US and the UK, and the companys psoriatic arthritis drug Adalimumab, known as Humira, facing biosimilar rivals in the US from 2023. RHHBY vs. ABBV: Which Stock Is the Better Value Option? All Rights Reserved. These products are not suitable for everyone and you should therefore consider your objectives, financial situation, needs and experience with these products before investing in them. AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.". To summarize, Humira may be going off-patent, but is more than capable of delivering double-digit billion revenues for another 3-4 years, and even in 2030, it could be amongst the top 20 best-selling drugs worldwide. If you rely on the information on this page then you do so entirely on your own risk. Sales of the drug reached $19.9bn in 2018 and were $19.2bn, $19.8bn and $20.6bn in 2019, 2020, and 2021 respectively. I suspect Eye Care is a division AbbVie can turn around given time, and I feel that with regards to oncology, where AbbVie has the strongest pipeline assets - lymphoma bispecific Epcoritamab may be approved to treat large B-cell lymphoma, and peak sales estimates range from $1.5 - $3bn, although AbbVie will not earn all of that since the product is co-developed with Genmab. $163.64. We're currently running a sale at my private investing ideas service, Haggerston BioHealth, where members get access to portfolios, market alerts, real-time chat, and more. Your current $100 investment may be up to $188.28 in 2028. z o.o., AbbVie Productos Farmacuticos Limitada, AbbVie Products LLC, AbbVie Promoo L.da, AbbVie Pte. I do much more than just articles at Haggerston BioHealth: Members get access to model portfolios, regular updates, a chat room, and more. On the negative side of things, we can see that AbbVie is no longer breaking out sales within its Women's Health division, with revenues lumped into the "all other section, presumably. Eye Care, Other products Division Projected Revenues to 2030 (my table and assumptions ). In terms of market cap, it ranks third behind Pfizer ( PFE) and Novo Nordisk ( NVO ). We expect proof-of-concept data from roughly a dozen additional early stage oncology opportunities over the next couple of years. Other approved ADC's targeting the c-Met protein, a validated target in NSCLC, include Novartis Tabrecta, which has been pegged for peak sales of ~$1.5bn, which seems a realistic target for Teliso given how large the lung cancer market is - the largest of all oncology markets. I wrote this article myself, and it expresses my own opinions. The company reported $3.60 EPS for the quarter, topping the consensus estimate of $3.54 by $0.06. Read our dividend analysis for ABBV. In the next year, analysts expect Free Cash Flow to reach $26.97B - an increase of 58.68%. Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. Gene therapies have been a long time coming, having first been popularized in the early noughties. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. Without the additional patents - >130 in total - Humira would have lost its market exclusivity in 2016, but having eventually lost protection in Europe, which has resulted in a sales decline from $6.3bn in 2018, to ~$2.7bn in 2022, Humira will finally face generic competition in the US from the beginning of this year. The total revenue in 2021 was $56.20 billion with a 31% operating margin. Top institutional shareholders include Geode Capital Management LLC (1.91%), Morgan Stanley (1.79%), Moneta Group Investment Advisors LLC (1.65%), Price T Rowe Associates Inc. MD (1.15%), Norges Bank (1.06%) and Legal & General Group Plc (0.66%). Wallet Investor suggested that the price could hit $300.386 in June 2027. The major market events for the week ahead right in your inbox. Move your mouse over a quarter or year to see how estimates have changed over time. The dividend payout ratio is 89.56%. Compare Top Brokerages Here. Stock Price Forecast The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 3.83%. As of February 15th, there was short interest totaling 11,710,000 shares, an increase of 13.7% from the January 31st total of 10,300,000 shares. You should consider whether you understand how CFDs work and can afford the risks. AbbVie Inc. (NYSE:ABBV) posted its earnings results on Thursday, February, 9th. AbbVie's stock is owned by many different institutional and retail investors. I am not receiving compensation for it (other than from Seeking Alpha). With AbbVie seemingly very confident of approvals for all 3 of these drugs, and Gonzalez suggesting they could form the basis of a "$6 billion kind of franchise" I have modelled for such an outcome by 2030. After 2022 Humira's row is shaded yellow to signify patent expiry. The dividend payout ratio of AbbVie is 89.56%. In the last two years, Aurora Cannabis's Revenue has fallen from C$245.54M to C$245.25M - a 0.12% decrease. As well as the stock price gains AbbVie has always paid a handsome dividend - which has increased by 270% since the Pharma's inception, currently paying $1.48 per quarter, for a current yield of 4% - the highest in the large Pharmaceutical sector. When looking for ABBV stock forecasts, it's important to bear in mind that analysts' forecasts can be wrong. Past performance is no guarantee of future results. Abbvie Stock Forecast 2023 In the Biopharmaceutical Industry, Abbvie has been able to create a leadership position in the market in each business segment with different brand names in different business categories like Immunology, Hematologic Oncology, Neuroscience, Aesthetics, and Eye Care. AbbVie has 5 focus areas for its research and products. It . Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing. This suggests a possible upside of 3.8% from the stock's current price. (my tables). Rinvoq's progress has been a little more circumspect, but almost as impressive. I believe AbbVie is likely 15 - 20% undervalued at current price. I hope to see you there. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over pastmonths for detail. Read the conference call transcript. For the next year, analysts predict that Free Cash Flow will reach 6.91B - an increase of 1.94%. What is AbbVie's stock price forecast for 2023? AbbVie made the bold decision to take on a heavy debt load and bid for Allergan, with the deal being completed in 2020. The company provided earnings per share (EPS) guidance of $10.70- for the period.

Dallas Sidekicks Salary, North American Championship Bodybuilding, Sigma Guitar Est 1970, Icon Golf Cart Charging Issues, Slingshot Helmet Laws By State, Articles A